AtriCure to Spotlight Growth Story at Key Investor Conference

MASON, OH – February 24, 2026 – Medical device innovator AtriCure, Inc. (Nasdaq: ATRC) is preparing to take the stage at the upcoming Citizens Life Sciences Conference, providing a crucial platform for management to detail its growth strategy to the investment community. The scheduled fireside chat on March 10 comes just weeks after the company posted impressive financial results for 2025, setting a confident tone as it navigates an increasingly competitive landscape in cardiac care.

Investors and analysts will be listening intently as AtriCure's leadership outlines the path forward. The presentation is an opportunity to build on recent momentum and address key questions about market share, product adoption, and the company's position against industry giants and disruptive new technologies.

A Financial Picture of Robust Health

AtriCure heads to the Miami conference backed by a strong tailwind of positive financial performance. The company recently announced its fourth-quarter and full-year 2025 results on February 17, outshining market expectations and signaling a firm trajectory toward sustained profitability.

For the fourth quarter of 2025, revenue climbed to $140.5 million, a 13.1% increase over the same period in the prior year. This growth was largely fueled by robust U.S. sales, which rose 12.6% to $114.3 million. For the full year, AtriCure reported total revenue of $534.5 million, up nearly 15% from 2024.

Perhaps more significantly for investors, the company demonstrated substantial progress on its bottom line. The net loss per share for 2025 was trimmed to just $0.24, a dramatic improvement from the $0.95 loss reported in 2024. Adjusted EBITDA, a key measure of operational profitability, nearly doubled to $61.8 million for the year. This financial strengthening has allowed management to issue an optimistic outlook for 2026, projecting revenue between $600 million and $610 million and a move into positive net earnings per share for the full year.

Innovation Driving a Diversified Portfolio

At the heart of AtriCure's growth story is a diversified portfolio of innovative technologies targeting atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain. This multi-pronged approach has enabled the company to capture share across different segments of cardiac and thoracic surgery.

The company’s appendage management franchise remains a cornerstone of its success. The AtriClip® system, particularly with newer devices like the FLEX-Mini®, is the most widely sold LAA management solution globally. LAA management is a critical procedure for reducing stroke risk in Afib patients, and AtriCure's leadership in this space is a significant competitive advantage.

In the realm of Afib treatment, the Isolator® Synergy™ Ablation System holds the distinction of being the first device ever approved by the FDA for treating persistent Afib, a more challenging form of the condition. Furthermore, AtriCure's Hybrid AF™ Therapy offers a novel, minimally invasive solution for patients with long-standing persistent Afib, a group for whom traditional treatments often fail. Clinical data from the CONVERGE trial has shown this combination therapy to be significantly more effective than catheter ablation alone, addressing a major unmet need in a patient population numbering in the millions.

Beyond cardiac rhythm, AtriCure has established a powerful new growth engine in post-operative pain management. Its cryoICE® platform, featuring the recently launched cryoSPHERE MAX™ probe, provides a non-opioid solution for blocking pain following cardiac and thoracic surgeries. This technology, which uses cryoablation to temporarily freeze peripheral nerves, has been a key driver of recent growth and is rapidly becoming a standard of care for surgeons looking to reduce patient reliance on narcotics.

Navigating a Crowded and Evolving Market

While AtriCure's performance is strong, it does not operate in a vacuum. The market for Afib and cardiac devices is intensely competitive, dominated by medical technology titans such as Medtronic, Abbott, Johnson & Johnson's Biosense Webster, and Boston Scientific. These "Big Four" competitors command significant resources and market share.

A central topic of discussion among investors is the rapid emergence of pulsed field ablation (PFA), a new energy source for treating Afib that promises safer and more efficient procedures. Major competitors are investing heavily in PFA, with several systems recently gaining regulatory approval and beginning commercial rollouts. Analysts are closely watching how this technological shift will impact the market for traditional radiofrequency and cryoablation devices, which form the basis of AtriCure's ablation offerings.

The company's ability to defend its market share and articulate its value proposition against the PFA wave will be a critical theme at the conference. Its focus on the surgical treatment of persistent and long-standing persistent Afib, as well as its dominant position in the concomitant LAA management market, may provide a durable moat. Ongoing clinical trials, such as the BoxX-NoAF study aimed at preventing post-operative Afib, could further expand its addressable market and solidify its role in the cardiac surgery workflow.

Wall Street's Bullish but Watchful Eye

Current sentiment from financial analysts is overwhelmingly positive. The consensus rating for ATRC stock is a "Strong Buy" among many firms, with average price targets suggesting a potential upside of over 70% from its current valuation. Analysts frequently cite the company's consistent double-digit revenue growth, expanding product portfolio, and clear path to profitability as key reasons for their bullish stance.

One market observer noted in a recent report that AtriCure is "uniquely positioned with a diversified portfolio that addresses critical unmet needs in cardiac surgery." They highlighted the pain management franchise as a particularly strong growth driver that differentiates the company from pure-play Afib competitors.

However, this optimism is tempered with caution. The competitive threat from PFA remains the most cited risk. Investors will also be looking for continued improvement in operating margins and free cash flow. While most segments are growing, the company has noted some headwinds in its U.S. minimally invasive surgery business, a detail that management will likely be asked to elaborate on. The upcoming fireside chat offers a prime opportunity for AtriCure to reinforce investor confidence, showcasing how its strategic focus on surgical solutions and diversified technologies will fuel the next chapter of its growth.